Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2005-07-12
2005-07-12
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S455000, C435S456000, C435S069100, C514S04400A
Reexamination Certificate
active
06916470
ABSTRACT:
Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+and CD34+sub-populations (CD34+Lin−, CD34+Thy-1+Lin−, and CD34+Lin−Rh123lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
REFERENCES:
patent: 4714680 (1987-12-01), Civin
patent: 5061620 (1991-10-01), Tsukamoto et al.
patent: 5147784 (1992-09-01), Peault
patent: 5728581 (1998-03-01), Schwartz et al.
patent: 5989537 (1999-11-01), Holly et al.
patent: WO 92/11355 (1992-07-01), None
patent: WO 95/03693 (1995-02-01), None
patent: WO 95/21626 (1995-08-01), None
patent: WO 96/40876 (1996-12-01), None
Baum, et al., “Isolation of a Candidate Human Hematopoietic Stem-Cell Population,”Proc. Natl. Acad. Sci., USA, 89:2804-2808 (Apr. 1992).
Bartley, et al., “Identification and Cloning of a Megakaryocyte Growth and Development Factor that is a Ligand for the Cytokine Receptor Mpl,”Cell, 77:1117-1124 (Jul. 1, 1994).
Berenson, et al., “Engraftment After Infusion of CD34+Marrow Cells in Patients with Breast Cancer or Neuroblastoma,”Blood, 77(8):1717-1722 (Apr. 15, 1991).
Bruno, et al.,Blood, 86(10):Abstract 1449 (1995).
Chen, et al., “Engraftment of Human Hematopoietic Precursor Cells Secondary Transfer Potential in SCID-hu Mice,”Blood, 84(8):2497-2505 (Oct. 15, 1994).
Choi, et al., “Platelets Generated In Vitro From Proplatelet-Displaying Human Megakaryocytes are Functional,”Blood, 85(2):402-413 (Jan. 15, 1995).
Craig, et al., “Expression of Thy-1 on Human Hematopoietic Progenitor Cells,”J. Exp. Med., 177:1331-1342 (May 1993).
Debili, et al., “The mpl Receptor is Expressed in the Megakaryocytic Lineage from Late Progenitors to Platelets,”Blood, 85(2):391-401 (Jan. 15, 1995).
de Sauvage, et al., “Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-mpl Ligand,”Nature, 369:533-538 (Jun. 16, 1994).
de Sauvage, et al., “Physiological Regulation of Early and Late Stages of Megakaryocytopoiesis by Thrombopoietin,”Journal of Experimental Medicine, 183:651-656 (Feb. 1, 1996).
Eck, et al., “Gene-Based Therapy,” in Goodman & Gilman'sThe Pharmacological Basis of Therapeutics, McGraw-Hill: New York, Ninth Edition, pp. 77-101 (1996).
Gurney, et al., “Thrombocytopenia in c-mpl-Deficient Mice,”Science, 265:1445-1447 (Sep. 1994).
Jorgensen, et al.,Blood, 84(10):Abstract 1301 (1994).
Kaushansky, et al., “Thrombopoietin Expands Erythroid Progenitors, Increases Red Cell Production, and Enhances Erythroid Recovery After Myelosuppressive Therapy,”J. Clin. Invest.96:1683-1687 (1995).
Kaushansky, et al., “Promotion of Megakaryocyte Progenitor Expansion and Differentiation by the c-Mpl Ligand Thrombopoietin,”Nature, 369:568-571 (1994).
Kaushansky, et al., “The mpl Ligand: Molecular and Cellular Biology of the Critical Regulator of Megakaryocyte Development,”Stem Cells, 12:91-97 (1994).
Lok, et al., “The Structure, Biology and Potential Therapeutic Applications of Recombinant Thrombopoietin,”Stem Cells, 12:586-598 (Nov. 1994).
Lu, et al., “High Efficiency Retroviral Mediated Gene Transduction into Single Isolated Immature and Replatable CD34(3+) Hematopoietic Stem/Progenitor Cells from Human Umbilical Cord Blood,”Journal of Experimental Medicine, 178:2089-2096 (Dec. 1993).
Mitani, et al., “Transduction of Human Bone Marrow by Adenoviral Vector,”Human Gene Therapy, 5:941-948 (Aug. 1994).
Murray, et al., “Analysis of Human Hematopoietic Stem Cell Populations,”Blood Cells, 20:364-370 (1994).
Murray, et al., “Enrichment of Human Hematopoietic Stem Cell Activity in the CD34+Thy-1+Lin Subpopulation from Mobilized Peripheral,”Blood, 85(2):368-378 (Jan. 15, 1995).
Reading, et al., Proceedings of ISEH Meeting 1994, Abstract,Exp. Hematol., 22:786 (1994).
Schmidt-Wolf, et al.,Journal of Hematotherapy, 4:551-561 (1995).
Spangrude, et al., “Purification and Characterization of Mouse Multipotent Hematopoietic Stem Cells,”Science, 241:58-62 (Jul. 1988).
Spangrude, et al., “Resting and Activated Subsets of Mouse Hematopoietic Stem Cells,”Proc. Natl. Acad. Sci, USA, 7433-7437 (Oct. 1990).
Sutherland, et al., “Differential Sensitivity of cd34 Epitopes to Cleavage by Pastereulia Haemolytica Glycoprotease: Implications for Purification of cd34-positive Progenitor Cells,”Exp. Hematol., 20:590-599 (1992).
Young, et al.,Blood, 88:1619-1631 (Sep. 1, 1996).
Zeigler, et al., “In Vitro Megakaryocytopoietic and Thrombopoietic Activity of c-mpl Ligand (TPO) on Purified Murine Hematopoietic Stem Cells,”Blood, 84(12)4045-4052 (Dec. 1994).
Murray Lesley J.
Young Judy C.
Fish & Neave IP Group of Ropes & Gray LLP
McGarry Sean
Novartis AG
LandOfFree
Methods for use of mpl ligands with primitive human stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for use of mpl ligands with primitive human stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for use of mpl ligands with primitive human stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3417971